Homepage > Company > Media > Pharma News > 2021 > NIH reports interferon is ineffective in hospitalised Covid-19 patients

NIH reports interferon is ineffective in hospitalised Covid-19 patients

The National Institutes of Health (NIH) in the US has reported that interferon beta-1a in combination with remdesivir did not boost outcomes in an ACTT-3 clinical trial in hospitalised adult Covid-19 pneumonia patients.

Interferon beta-1a: Uses, Interactions, Mechanism of Action | DrugBank Online

A multiple sclerosis therapy, subcutaneous interferon beta-1a is produced and marketed by Merck KGaA, Darmstadt, Germany in the US while remdesivir is an antiviral manufactured by Gilead Sciences.

Sponsored and funded by NIH unit National Institute of Allergy and Infectious Diseases (NIAID), the trial recruited 969 subjects.

October 19th, 2021

https://www.clinicaltrialsarena.com/

Read also

uniQure Staggers as FDA Questions Data for Huntington’s Gene Therapy Candidate

Agency torpedoes company's plans to submit BLA for gene therapy AMT-130 in Q1 2026.

Kimberly-Clark buys troubled Tylenol-maker Kenvue for $48.7bn

Kimberly-Clark has agreed to acquire Johnson & Johnson (J&J) consumer health spinout Kenvue for $48.7bn.

Femasys gets FDA OK for final FemBloc trial, secures $12M financing, stock surges

Femasys (FEMY) on Monday said that the FDA approved continuation of the final phase of its FemBloc pivotal trial, sending shares 25% higher in premarket trading.

Praxis announces

Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback